In vitro evaluation of the protective role of human antibodies to West Nile virus (WNV) produced during natural WNV infection.

BACKGROUND West Nile virus (WNV) is endemic in the United States and transmissible by transfusion. Since 2003, the US blood supply has been screened by nucleic-acid tests (NAT) for WNV in minipools (MP-NAT) of 6 or 16 specimens. WNV infection begins with low-level viremia detectable only by individual testing (ID-NAT) and no detectable WNV antibodies. Viremia then increases to levels detectable by MP-NAT, and antibodies become detectable; later, viremia decays to levels detectable only by ID-NAT before becoming undetectable. All but 1 documented WNV transmission by transfusion involved blood components negative for WNV antibodies, raising the question whether WNV antibody-positive blood components with low levels of WNV RNA are infectious. METHODS Specimens from 102 viremic donors with and without WNV antibodies were used to investigate infectivity in cultures of Vero cells and human monocyte-derived macrophages (MDMs). RESULTS In Vero cell culture, 54 (74%) of 73 WNV antibody-negative specimens and 10 (36%) of 28 WNV antibody-positive specimens were infectious. In a random subset of 20 specimens tested in MDM culture, 7 (88%) of 8 WNV antibody-positive specimens and 12 (100%) of 12 WNV antibody-negative specimens were infectious. CONCLUSION WNV antibodies do not always protect susceptible cells from WNV infection in vitro. RNA positivity in the presence of antibody cannot be ignored as a theoretical risk for blood recipients and needs further investigation.

[1]  I. Hewlett,et al.  Monocytes‐macrophages are a potential target in human infection with West Nile virus through blood transfusion , 2006, Transfusion.

[2]  Peter Tomasulo,et al.  Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. , 2005, The New England journal of medicine.

[3]  G. Foster,et al.  West Nile virus among blood donors in the United States, 2003 and 2004. , 2005, The New England journal of medicine.

[4]  M. Drebot,et al.  Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003 , 2005, Transfusion.

[5]  H. Nauwynck,et al.  West Nile virus in the vertebrate world , 2005, Archives of Virology.

[6]  Daniel R. O’Leary,et al.  The epidemic of West Nile virus in the United States, 2002. , 2004, Vector borne and zoonotic diseases.

[7]  T. Leary,et al.  Enzyme-Linked Immunosorbent Assays Using Recombinant Envelope Protein Expressed in COS-1 and Drosophila S2 Cells for Detection of West Nile Virus Immunoglobulin M in Serum or Cerebrospinal Fluid , 2004, Clinical Diagnostic Laboratory Immunology.

[8]  A. Barrett,et al.  Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. , 2004, The Journal of infectious diseases.

[9]  W. Hogrefe,et al.  Utility of the Focus Technologies West Nile Virus Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assay for Testing Cerebrospinal Fluid , 2004, Journal of Clinical Microbiology.

[10]  R. Lanciotti,et al.  Transmission of West Nile virus through blood transfusion in the United States in 2002. , 2003, The New England journal of medicine.

[11]  W. Hogrefe,et al.  Detection of West Nile Virus (WNV)-Specific Immunoglobulin M in a Reference Laboratory Setting during the 2002 WNV Season in the United States , 2003, Clinical Diagnostic Laboratory Immunology.

[12]  Denise A. Martin,et al.  Immunoassay Targeting Nonstructural Protein 5 To Differentiate West Nile Virus Infection from Dengue and St. Louis Encephalitis Virus Infections and from Flavivirus Vaccination , 2003, Journal of Clinical Microbiology.

[13]  J. P. Montgomery,et al.  Possible West Nile virus transmission to an infant through breast-feeding--Michigan, 2002. , 2002, MMWR. Morbidity and mortality weekly report.

[14]  Denise A. Martin,et al.  Use of Immunoglobulin M Cross-Reactions in Differential Diagnosis of Human Flaviviral Encephalitis Infections in the United States , 2002, Clinical and Vaccine Immunology.

[15]  Transfusion-associated transmission of West Nile virus--Arizona, 2004. , 2004, MMWR. Morbidity and mortality weekly report.

[16]  J. Gerberding,et al.  Update: West Nile virus screening of blood donations and transfusion-associated transmission--United States, 2003. , 2004, MMWR. Morbidity and mortality weekly report.

[17]  G. Kuno.  Serodiagnosis of flaviviral infections and vaccinations in humans. , 2003, Advances in virus research.

[18]  Update: Investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion--Michigan, 2002. , 2002, MMWR. Morbidity and mortality weekly report.

[19]  D. Nash.  Outbreak of West Nile-Like Viral Encephalitis -- New York, 1999 , 1999 .

[20]  D. Cimini,et al.  Outbreak of West Nile-like viral encephalitis--New York, 1999. , 1999, MMWR. Morbidity and mortality weekly report.

[21]  Á. Száz.  Minimal structures , generalized topologies , and ascending systems should not be studied without generalized uniformities , 2007 .